BR112019023979A2 - compostos, composições e métodos - Google Patents
compostos, composições e métodos Download PDFInfo
- Publication number
- BR112019023979A2 BR112019023979A2 BR112019023979A BR112019023979A BR112019023979A2 BR 112019023979 A2 BR112019023979 A2 BR 112019023979A2 BR 112019023979 A BR112019023979 A BR 112019023979A BR 112019023979 A BR112019023979 A BR 112019023979A BR 112019023979 A2 BR112019023979 A2 BR 112019023979A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- compounds
- inflammation
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507682P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/033269 WO2018213634A1 (en) | 2017-05-17 | 2018-05-17 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023979A2 true BR112019023979A2 (pt) | 2020-06-09 |
Family
ID=64274734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023979A BR112019023979A2 (pt) | 2017-05-17 | 2018-05-17 | compostos, composições e métodos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11174262B2 (https=) |
| EP (1) | EP3625234B1 (https=) |
| JP (2) | JP7140781B2 (https=) |
| KR (1) | KR102637541B1 (https=) |
| CN (1) | CN110914275A (https=) |
| AU (2) | AU2018269745C1 (https=) |
| BR (1) | BR112019023979A2 (https=) |
| CA (1) | CA3063938A1 (https=) |
| IL (1) | IL270505B2 (https=) |
| MX (1) | MX2019013642A (https=) |
| WO (1) | WO2018213634A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP2023540223A (ja) * | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| EP4422621A4 (en) * | 2021-10-27 | 2025-08-27 | Merck Sharp & Dohme Llc | SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF |
| WO2025045281A2 (zh) * | 2023-08-31 | 2025-03-06 | 杭州百诚医药科技股份有限公司 | 苯并氮杂䓬酮类化合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4290952A (en) * | 1980-06-23 | 1981-09-22 | American Home Products Corporation | Aryl-1-mercaptoalkanoylproline and homoproline derivatives |
| US4320057A (en) * | 1980-06-23 | 1982-03-16 | American Home Products Corporation | Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones |
| US7932382B2 (en) * | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| JP2008545780A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| KR20090041391A (ko) * | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 ｉａｐ 길항제 |
| JP6465803B2 (ja) * | 2012-10-22 | 2019-02-06 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ｅｔｐ誘導体 |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP3229807A4 (en) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Inhibitors of cellular necrosis and related methods |
| HK1244792B (en) * | 2014-12-24 | 2019-07-12 | 北京生命科学研究所 | Necrosis inhibitors |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2018
- 2018-05-17 CA CA3063938A patent/CA3063938A1/en active Pending
- 2018-05-17 KR KR1020197036801A patent/KR102637541B1/ko active Active
- 2018-05-17 WO PCT/US2018/033269 patent/WO2018213634A1/en not_active Ceased
- 2018-05-17 EP EP18803112.4A patent/EP3625234B1/en active Active
- 2018-05-17 IL IL270505A patent/IL270505B2/en unknown
- 2018-05-17 AU AU2018269745A patent/AU2018269745C1/en not_active Ceased
- 2018-05-17 CN CN201880047315.8A patent/CN110914275A/zh active Pending
- 2018-05-17 JP JP2019563609A patent/JP7140781B2/ja active Active
- 2018-05-17 BR BR112019023979A patent/BR112019023979A2/pt active Search and Examination
- 2018-05-17 MX MX2019013642A patent/MX2019013642A/es unknown
-
2019
- 2019-11-14 US US16/683,970 patent/US11174262B2/en active Active
-
2021
- 2021-10-05 US US17/494,336 patent/US11851433B2/en active Active
-
2022
- 2022-04-14 AU AU2022202524A patent/AU2022202524B2/en not_active Ceased
- 2022-09-07 JP JP2022141824A patent/JP2022174180A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP7140781B2 (ja) | 2022-09-21 |
| EP3625234A1 (en) | 2020-03-25 |
| MX2019013642A (es) | 2020-07-20 |
| US20220024938A1 (en) | 2022-01-27 |
| CA3063938A1 (en) | 2018-11-22 |
| EP3625234A4 (en) | 2021-03-10 |
| IL270505A (https=) | 2019-12-31 |
| US11174262B2 (en) | 2021-11-16 |
| AU2018269745C1 (en) | 2022-06-09 |
| AU2022202524A1 (en) | 2022-05-12 |
| WO2018213634A1 (en) | 2018-11-22 |
| KR20200006120A (ko) | 2020-01-17 |
| KR102637541B1 (ko) | 2024-02-15 |
| US20200079784A1 (en) | 2020-03-12 |
| JP2022174180A (ja) | 2022-11-22 |
| AU2022202524B2 (en) | 2023-10-05 |
| US11851433B2 (en) | 2023-12-26 |
| IL270505B2 (en) | 2023-09-01 |
| JP2020520925A (ja) | 2020-07-16 |
| AU2018269745B2 (en) | 2022-01-27 |
| IL270505B1 (en) | 2023-05-01 |
| EP3625234B1 (en) | 2023-09-20 |
| AU2018269745A1 (en) | 2019-11-28 |
| CN110914275A (zh) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023979A2 (pt) | compostos, composições e métodos | |
| CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| BR112017025004A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112018010089A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112019018124A2 (pt) | composições e métodos para imunooncologia | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| BR112018009706A2 (pt) | composições compreendendo cepas bacterianas | |
| UY35488A (es) | Xantinas sustituidas y métodos para su uso | |
| BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| CU20190006A7 (es) | Composiciones para inhibir masp-3 | |
| MX2021008376A (es) | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. | |
| EA201992177A1 (ru) | Композиции на основе нирапариба | |
| CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| EA201691194A1 (ru) | Стимуляторы ргц | |
| UY35424A (es) | Xantinas sustituidas y métodos para su uso | |
| MX2020010657A (es) | Derivados de oxadiazolina. | |
| MX2015016585A (es) | Una composicion para aplicacion topica que comprende glicerol y taninos. | |
| CL2018003028A1 (es) | Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016). | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| MX395699B (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
| MX386158B (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos | |
| CL2017002694A1 (es) | Métodos para mejora hidráulica de cultivos | |
| BR112017013770A2 (pt) | composições de inibidor de nitrificação microencapsuladas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 487/10 , C07D 495/14 , C07D 495/20 Ipc: C07D 487/10 (2006.01), C07D 495/14 (2006.01), C07D |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |